UK regulators warn of ocular side effects after treatment with Sanofi's Dupixent

After five years of Dupixent’s reign for Sanofi, the U.K.'s medicines regulatory agency is warning about the risks of ocular side effects.

In a Tuesday update from the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA), officials noted risks of ocular reactions that are usually mild but can become serious if "not managed properly."